Racura Oncology (ASX:RAC)
ASX announcement history & article coverage
Transparent by design.
Announcments by Racura Oncology (ASX:RAC) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification regarding unquoted securities - RAC
CPACS Trial Opens for RC220 Patient Enrolment in Korea
Racura Oncology Opens Korean Sites for CPACS Trial Patient Enrolment
Corporate Governance Statement
Appendix 4G
Appendix 4E & Annual Report
Racura Oncology reports $11.1M loss, advances MYC-targeting cancer drug with strong funding
Racure Oncology Techknow Invest Presentation
First HARNESS-1 Patient Safely Treated with RC220
Racura Oncology's HARNESS-1 trial progresses with SRC review and additional patient dosing after Grade 2 colitis reported
June 2026 Quarterly Activities Report and Appendix 4C
Racura Oncology advances clinical trials and secures $34.3M cash runway into 2028
Notification of cessation of securities - RAC
Racura to Present CPACS Data at GCOS 2026
Racura Oncology New Zealand Investor Events
Bellberry Ethics Approval Activates New HARNESS Trial Sites
Bellberry Ethics Approval Enables Expansion of Racura's HARNESS-1 Lung Cancer Trial Sites
Notification of cessation of securities - RAC
Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
Racura Oncology Treats First Patient in Phase 1 HARNESS-1 Lung Cancer Trial
Racura Oncology Investor Briefings Perth & Auckland
Racura raised $34.3m to Advance Three Oncology Trials
Racura Oncology Raises $34.3 Million to Fund Three Oncology Clinical Trials
Cleansing Notice
Application for quotation of securities - RAC
Cleansing Notice
Application for quotation of securities - RAC
Appendix 3Y-Dr Serge Scrofani
Racura Options Raised $24.4m
Notification of cessation of securities - RAC
Proposed issue of securities - RAC
Emerging Companies Specialist Invests in Racura
Racura Oncology raises $31.2 million including $1 million private placement to specialist investor